Source link : https://www.newshealth.biz/health-news/fda-approves-mirdametinib-for-neurofibromatosis-type-1/
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically, the kinase inhibitor was approved for adults and children aged ≥ 2 years who have NF1 with symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection, according […]
Author : News Health
Publish date : 2025-02-12 04:13:54
Copyright for syndicated content belongs to the linked Source.